Insider Trading activities of Ionis Pharmaceuticals Inc insiders. , Part 4

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ionis Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ionis Pharmaceuticals Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Ionis Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is IONS. The reporting company's CIK number is 874015.
The total value of stock buying since 2005 is $90,940.
The total value of stock sales since 2005 is $144,899,499.
The total value of stock option exercises since 2005 is $47,126,023.



Table 2. Detailed insider stock purchases, sales, and option exercises of Ionis Pharmaceuticals Inc insiders (IONS) , Part 4
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2013-07-11 Geary Richard S (SVP, Development) Sale 9,000 31.90 287,100
2013-07-11 Geary Richard S (SVP, Development) Option Ex 9,000 11.12 100,080
2013-07-11 Crooke Stanley T (Chairman and CEO) Sale 30,000 32.00 960,090
2013-07-11 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 15.38 461,400
2013-07-10 Crooke Stanley T (Chairman and CEO) Sale 30,000 30.05 901,440
2013-07-10 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 15.38 461,400
2013-07-09 Geary Richard S (SVP, Development) Sale 10,358 30.04 311,185
2013-07-09 Geary Richard S (SVP, Development) Option Ex 10,358 10.29 106,583
2013-07-09 Crooke Stanley T (Chairman and CEO) Sale 30,000 30.04 901,290
2013-07-09 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 15.38 461,400
2013-07-08 Geary Richard S (SVP, Development) Sale 30,000 30.07 902,070
2013-07-08 Geary Richard S (SVP, Development) Option Ex 30,000 10.94 328,290
2013-07-08 Crooke Stanley T (Chairman and CEO) Sale 54,992 25.16 1,383,873
2013-07-08 Crooke Stanley T (Chairman and CEO) Option Ex 5,008 15.38 77,023
2013-07-05 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 277 29.25 8,102
2013-07-05 Geary Richard S (SVP, Development) Sale 25,805 29.82 769,608
2013-07-05 Geary Richard S (SVP, Development) Option Ex 24,180 14.94 361,249
2013-07-05 Crooke Stanley T (Chairman and CEO) Sale 24,180 30.02 725,762
2013-07-05 Crooke Stanley T (Chairman and CEO) Option Ex 24,180 15.38 371,888
2013-07-03 Geary Richard S (SVP, Development) Sale 5,000 29.02 145,100
2013-07-03 Geary Richard S (SVP, Development) Option Ex 5,000 19.08 95,399
2013-07-02 Monia Brett P (SVP, Antisense Drug Discovery) Sale 215 28.70 6,169
2013-07-02 Klein Joseph Iii (Director) Option Ex 313 .00 0
2013-07-02 Muto Frederick T (Director) Option Ex 313 .00 0
2013-07-02 Berthelsen Spencer R (Director) Option Ex 313 .00 0
2013-07-02 Wender Joseph H (Director) Option Ex 313 .00 0
2013-07-01 Crooke Stanley T (Chairman and CEO) Sale 10,000 28.17 281,700
2013-06-28 Crooke Stanley T (Chairman and CEO) Sale 20,683 27.23 563,198
2013-06-28 Crooke Stanley T (Chairman and CEO) Option Ex 20,683 8.25 170,572
2013-06-27 Crooke Stanley T (Chairman and CEO) Sale 20,000 27.85 557,000
2013-06-27 Crooke Stanley T (Chairman and CEO) Option Ex 20,000 6.81 136,200
2013-06-26 Crooke Stanley T (Chairman and CEO) Sale 30,000 26.90 807,030
2013-06-26 Crooke Stanley T (Chairman and CEO) Option Ex 20,000 6.81 136,200
2013-06-25 Geary Richard S (SVP, Development) Sale 17,049 28.02 477,644
2013-06-25 Geary Richard S (SVP, Development) Option Ex 17,049 12.78 217,937
2013-06-25 Crooke Stanley T (Chairman and CEO) Sale 30,000 28.09 842,790
2013-06-25 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 6.81 204,300
2013-06-24 Geary Richard S (SVP, Development) Sale 30,000 25.18 755,400
2013-06-24 Geary Richard S (SVP, Development) Option Ex 30,000 15.50 465,090
2013-06-24 Crooke Stanley T (Chairman and CEO) Sale 30,000 25.19 755,700
2013-06-20 Wender Joseph H (Director) Sale 5,447 20.93 114,005
2013-06-20 Wender Joseph H (Director) Option Ex 10,000 5.17 51,700
2013-06-11 Monia Brett P (SVP, Antisense Drug Discovery) Sale 9,375 23.76 222,750
2013-06-11 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 9,375 15.75 147,656
2013-05-30 Muto Frederick T (Director) Sale 10,000 21.96 219,600
2013-05-30 Muto Frederick T (Director) Option Ex 10,000 5.17 51,700
2013-05-01 Bennett C Frank (SVP, Antisense Research) Sale 29,945 22.26 666,605
2013-05-01 Bennett C Frank (SVP, Antisense Research) Option Ex 29,945 8.96 268,456
2013-04-30 Bennett C Frank (SVP, Antisense Research) Sale 30,000 22.50 675,150
2013-04-30 Bennett C Frank (SVP, Antisense Research) Option Ex 30,000 11.12 333,600
2013-04-25 Parshall B Lynne (COO, Secretary) Sale 25,854 22.50 581,585
2013-04-25 Parshall B Lynne (COO, Secretary) Option Ex 25,854 8.96 231,781
2013-04-24 Hougen Elizabeth L (SVP, Finance & CFO) Sale 10,417 22.38 233,132
2013-04-24 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 10,417 15.38 160,213
2013-04-24 Parshall B Lynne (COO, Secretary) Sale 30,000 22.12 663,600
2013-04-24 Parshall B Lynne (COO, Secretary) Option Ex 30,000 11.12 333,600
2013-04-24 Crooke Stanley T (Chairman, CEO and President) Sale 10,000 22.12 221,200
2013-04-23 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 27,320 22.13 604,591
2013-04-23 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 27,320 12.27 335,079
2013-04-23 Parshall B Lynne (COO, Secretary) Sale 30,000 22.10 662,910
2013-04-23 Parshall B Lynne (COO, Secretary) Option Ex 30,000 8.25 247,410
2013-04-23 Crooke Stanley T (Chairman, CEO and President) Sale 30,000 22.10 662,910
2013-04-22 Monia Brett P (SVP, Antisense Drug Discovery) Sale 17,000 21.26 361,420
2013-04-22 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 17,000 11.12 189,040
2013-04-22 Hougen Elizabeth L (SVP, Finance & CFO) Sale 17,656 21.43 378,403
2013-04-22 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 17,656 15.15 267,541
2013-04-22 Parshall B Lynne (COO, Secretary) Sale 30,000 20.99 629,700
2013-04-22 Parshall B Lynne (COO, Secretary) Option Ex 30,000 11.12 333,600
2013-04-22 Crooke Stanley T (Chairman, CEO and President) Sale 30,000 20.99 629,700
2013-04-22 Crooke Stanley T (Chairman, CEO and President) Option Ex 20,000 7.26 145,200
2013-04-19 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 15,000 20.22 303,255
2013-04-19 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 15,000 14.85 222,780
2013-04-19 Monia Brett P (SVP, Antisense Drug Discovery) Sale 2,500 21.25 53,125
2013-04-19 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 2,500 11.12 27,799
2013-04-19 Geary Richard S (SVP, Development) Sale 2,042 20.80 42,473
2013-04-19 Geary Richard S (SVP, Development) Option Ex 2,042 11.12 22,707
2013-04-19 Parshall B Lynne (COO, Secretary) Sale 30,000 20.01 600,180
2013-04-19 Parshall B Lynne (COO, Secretary) Option Ex 30,000 7.26 217,800
2013-04-19 Crooke Stanley T (Chairman, CEO and President) Sale 30,000 20.01 600,180
2013-04-19 Crooke Stanley T (Chairman, CEO and President) Option Ex 30,000 7.26 217,800
2013-04-12 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 5,460 19.61 107,065
2013-04-12 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 5,460 14.32 78,214
2013-04-11 Geary Richard S (Sr VP, Development) Sale 7,000 19.52 136,640
2013-04-11 Geary Richard S (Sr VP, Development) Option Ex 7,000 11.12 77,840
2013-03-21 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 9,000 19.26 173,340
2013-03-21 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 9,000 14.18 127,620
2013-03-21 Geary Richard S (Sr VP, Development) Sale 1,000 19.50 19,500
2013-03-21 Geary Richard S (Sr VP, Development) Option Ex 1,000 11.12 11,120
2013-03-20 Klein Joseph Iii (Director) Sale 35,521 18.00 639,378
2013-03-20 Klein Joseph Iii (Director) Option Ex 35,521 10.82 393,721
2013-03-20 Hougen Elizabeth L (SVP, Finance and CFO) Sale 14,376 18.13 260,636
2013-03-20 Hougen Elizabeth L (SVP, Finance and CFO) Option Ex 14,376 11.12 159,861
2013-03-19 Klein Joseph Iii (Director) Sale 11,179 18.00 201,222
2013-03-19 Klein Joseph Iii (Director) Option Ex 11,179 5.93 66,291
2013-03-13 Klein Joseph Iii (Director) Sale 20,800 18.01 374,545
2013-03-13 Klein Joseph Iii (Director) Option Ex 20,800 5.55 115,440
2013-03-05 Monia Brett P (SVP, Antisense Drug Discovery) Sale 18,240 16.86 307,599
2013-03-05 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 18,240 6.81 124,214
2013-03-05 Hougen Elizabeth L (SVP, Finance and CFO) Sale 5,040 16.86 84,959
2013-03-05 Hougen Elizabeth L (SVP, Finance and CFO) Option Ex 5,040 6.81 34,322
2013-03-04 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 11,700 15.82 185,058
2013-03-04 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 11,700 11.20 130,981
2013-02-21 Berthelsen Spencer R (Director) Option Ex 10,000 5.17 51,700
2013-02-19 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,600 14.80 23,680
2013-02-19 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,600 10.29 16,464
2013-02-15 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 350 14.81 5,183
2013-02-15 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 350 10.29 3,601
2013-02-13 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 6,239 14.17 88,406
2013-02-13 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 6,100 7.62 46,512
2013-01-30 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 2,000 14.82 29,640
2013-01-30 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 2,000 10.29 20,580
2013-01-29 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 300 13.40 4,020
2013-01-17 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 242 14.16 3,426
2013-01-16 Monia Brett P (SVP, Antisense Drug Discovery) Sale 330 14.00 4,620
2013-01-16 Geary Richard S (SVP, Development) Sale 345 14.00 4,830
2013-01-16 Hougen Elizabeth L (SVP, Finance & CFO) Sale 242 14.00 3,388
2013-01-16 Bennett C Frank (SVP, Antisense Research) Sale 309 14.00 4,326
2013-01-16 Parshall B Lynne (COO, Secretary) Sale 759 14.00 10,626
2013-01-16 Crooke Stanley T (Chairman, CEO and President) Sale 1,460 14.00 20,440
2013-01-15 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 542 .00 0
2013-01-15 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 737 .00 0
2013-01-15 Geary Richard S (SVP, Development) Option Ex 776 .00 0
2013-01-15 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 542 .00 0
2013-01-15 Bennett C Frank (SVP, Antisense Research) Option Ex 695 .00 0
2013-01-15 Parshall B Lynne (COO, Secretary) Option Ex 1,715 .00 0
2013-01-15 Crooke Stanley T (Chairman, CEO and President) Option Ex 3,295 .00 0
2013-01-04 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 1,296 10.76 13,944
2013-01-03 Monia Brett P (VP, Antisense Drug Discovery) Sale 311 10.84 3,371
2013-01-03 Geary Richard S (Sr VP, Development) Sale 265 10.84 2,872
2012-12-13 Geary Richard S (Sr VP, Development) Sale 6,000 9.62 57,750
2012-12-13 Geary Richard S (Sr VP, Development) Option Ex 6,000 5.25 31,500
2012-09-21 Crooke Stanley T (Chairman, CEO and President) Sale 29,462 14.06 414,235
2012-09-21 Crooke Stanley T (Chairman, CEO and President) Option Ex 29,462 6.84 201,520
2012-09-20 Crooke Stanley T (Chairman, CEO and President) Sale 30,000 15.01 450,240
2012-09-20 Crooke Stanley T (Chairman, CEO and President) Option Ex 30,000 6.04 181,350
2012-09-19 Crooke Stanley T (Chairman, CEO and President) Sale 30,000 14.81 444,450
2012-09-19 Crooke Stanley T (Chairman, CEO and President) Option Ex 30,000 5.25 157,500
2012-09-13 Crooke Stanley T (Chairman, CEO and President) Sale 27,074 14.55 393,926
2012-09-13 Crooke Stanley T (Chairman, CEO and President) Option Ex 27,074 5.25 142,138
2012-09-07 Parshall B Lynne (COO, Secretary) Sale 12,506 15.12 189,090
2012-09-07 Parshall B Lynne (COO, Secretary) Option Ex 12,506 6.84 85,541
2012-09-06 Monia Brett P (VP, Antisense Drug Discovery) Sale 12,031 15.25 183,472
2012-09-06 Monia Brett P (VP, Antisense Drug Discovery) Option Ex 12,031 5.25 63,162
2012-09-06 Reed John C (Director) Sale 4,900 15.18 74,357
2012-09-06 Reed John C (Director) Option Ex 4,900 5.17 25,333
2012-09-06 Parshall B Lynne (COO, Secretary) Sale 30,000 15.02 450,630
2012-09-06 Parshall B Lynne (COO, Secretary) Option Ex 30,000 5.93 177,930
2012-09-06 Crooke Stanley T (Chairman, CEO and President) Sale 30,000 15.02 450,540
2012-09-06 Crooke Stanley T (Chairman, CEO and President) Option Ex 30,000 5.51 165,450
2012-09-05 Parshall B Lynne (COO, Secretary) Sale 2,000 15.00 30,000

Insider trading activities including stock purchases, stock sales, and option exercises of IONS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ionis Pharmaceuticals Inc (symbol IONS, CIK number 874015) see the Securities and Exchange Commission (SEC) website.